243 related articles for article (PubMed ID: 24659968)
1. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles.
Alsenaidy MA; Jain NK; Kim JH; Middaugh CR; Volkin DB
Front Pharmacol; 2014; 5():39. PubMed ID: 24659968
[TBL] [Abstract][Full Text] [Related]
2. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.
Alsenaidy MA; Kim JH; Majumdar R; Weis DD; Joshi SB; Tolbert TJ; Middaugh CR; Volkin DB
J Pharm Sci; 2013 Nov; 102(11):3942-56. PubMed ID: 24114789
[TBL] [Abstract][Full Text] [Related]
3. Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.
Alsenaidy MA; Okbazghi SZ; Kim JH; Joshi SB; Middaugh CR; Tolbert TJ; Volkin DB
J Pharm Sci; 2014 Jun; 103(6):1613-1627. PubMed ID: 24740840
[TBL] [Abstract][Full Text] [Related]
4. Improved Comparative Signature Diagrams to Evaluate Similarity of Storage Stability Profiles of Different IgG1 mAbs.
Kim JH; Joshi SB; Esfandiary R; Iyer V; Bishop SM; Volkin DB; Middaugh CR
J Pharm Sci; 2016 Mar; 105(3):1028-35. PubMed ID: 26886311
[TBL] [Abstract][Full Text] [Related]
5. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
6. An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.
Alsenaidy MA; Wang T; Kim JH; Joshi SB; Lee J; Blaber M; Volkin DB; Middaugh CR
Protein Sci; 2012 Mar; 21(3):418-32. PubMed ID: 22113934
[TBL] [Abstract][Full Text] [Related]
7. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations.
Iyer V; Maddux N; Hu L; Cheng W; Youssef AK; Winter G; Joshi SB; Volkin DB; Middaugh CR
J Pharm Sci; 2013 Jan; 102(1):43-51. PubMed ID: 23160989
[TBL] [Abstract][Full Text] [Related]
8. Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical Stability Profiles of IgG1-Fc Glycoforms.
More AS; Toprani VM; Okbazghi SZ; Kim JH; Joshi SB; Middaugh CR; Tolbert TJ; Volkin DB
J Pharm Sci; 2016 Feb; 105(2):588-601. PubMed ID: 26869421
[TBL] [Abstract][Full Text] [Related]
9. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.
Chaudhuri R; Cheng Y; Middaugh CR; Volkin DB
AAPS J; 2014 Jan; 16(1):48-64. PubMed ID: 24174400
[TBL] [Abstract][Full Text] [Related]
10. Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.
Kalonia C; Kumru OS; Kim JH; Middaugh CR; Volkin DB
J Pharm Sci; 2013 Dec; 102(12):4256-67. PubMed ID: 24122556
[TBL] [Abstract][Full Text] [Related]
11. Multidimensional methods for the formulation of biopharmaceuticals and vaccines.
Maddux NR; Joshi SB; Volkin DB; Ralston JP; Middaugh CR
J Pharm Sci; 2011 Oct; 100(10):4171-97. PubMed ID: 21647886
[TBL] [Abstract][Full Text] [Related]
12. T
Robinson MJ; Matejtschuk P; Bristow AF; Dalby PA
Mol Pharm; 2018 Jan; 15(1):256-267. PubMed ID: 29141152
[TBL] [Abstract][Full Text] [Related]
13. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
[TBL] [Abstract][Full Text] [Related]
14. Biosimilarity Assessments of Model IgG1-Fc Glycoforms Using a Machine Learning Approach.
Kim JH; Joshi SB; Tolbert TJ; Middaugh CR; Volkin DB; Smalter Hall A
J Pharm Sci; 2016 Feb; 105(2):602-612. PubMed ID: 26869422
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
16. Assessing analytical comparability of biosimilars: GCSF as a case study.
Nupur N; Singh SK; Narula G; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
[TBL] [Abstract][Full Text] [Related]
17. Redesigning food protein formulations with empirical phase diagrams: A case study on glycerol-poor and glycerol-free formulations.
Klijn ME; Hubbuch J
Food Res Int; 2019 Nov; 125():108609. PubMed ID: 31554045
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements.
Cheng W; Joshi SB; He F; Brems DN; He B; Kerwin BA; Volkin DB; Middaugh CR
J Pharm Sci; 2012 May; 101(5):1701-20. PubMed ID: 22323186
[TBL] [Abstract][Full Text] [Related]
19. Analytical lessons learned from selected therapeutic protein drug comparability studies.
Federici M; Lubiniecki A; Manikwar P; Volkin DB
Biologicals; 2013 May; 41(3):131-47. PubMed ID: 23146362
[TBL] [Abstract][Full Text] [Related]
20. Analytical Comparability Assessments of 5 Recombinant CRM
Hickey JM; Toprani VM; Kaur K; Mishra RPN; Goel A; Oganesyan N; Lees A; Sitrin R; Joshi SB; Volkin DB
J Pharm Sci; 2018 Jul; 107(7):1806-1819. PubMed ID: 29526446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
